Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
The EC has announced a targeted adjustment to intellectual property rules, a so-called ‘export manufacturing waiver’ to supple- mentary protection certificates, to help Europe’s pharmaceutical companies tap into fast-growing global markets. The proposal is accompanied by a series of safeguards, which will create transparency and prevent IP-infringing products from entering member state markets.
[/membership]
